Thomas Taapken
Director of Finance/CFO chez INFLARX N.V.
Fortune : 5 390 $ au 31/03/2024
Profil
Thomas Taapken is currently the Chief Executive Officer at Bluehaven Therapeutics AG, Chairman at ImCyse SA, Independent Director at SciBase Holding AB, Director at SciBase AB, and Independent Director at Memo Therapeutics AG.
He is also the Chief Financial Officer at elbion NV and Chief Financial Officer at InflaRx NV.
Previously, he served as CEO, CFO & Investor Relations Contact at Biotie Therapies Oy, Partner at Burrill LLC, Chief Executive & Financial Officer at MediGene AG, Chief Executive & Financial Officer at Epigenomics AG, and Chief Financial Officer at elbion AG.
He was also a Director at Immunic AG and a Principal at Sanofi-Aventis Deutschland GmbH.
Dr. Taapken holds a doctorate degree from the Technical University of Berlin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INFLARX N.V.
0,01% | 31/12/2023 | 3 500 ( 0,01% ) | 5 390 $ | 31/03/2024 |
Postes actifs de Thomas Taapken
| Sociétés | Poste | Début |
|---|---|---|
| SCIBASE HOLDING AB (PUBL) | Director/Board Member | 16/05/2017 |
| INFLARX N.V. | Director of Finance/CFO | 01/10/2020 |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Director of Finance/CFO | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Chairman | 01/01/2019 |
| Bluehaven Therapeutics AG | Chief Executive Officer | - |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Director/Board Member | 01/01/2021 |
| Scibase AB | Director/Board Member | 01/01/2017 |
Anciens postes connus de Thomas Taapken
| Sociétés | Poste | Fin |
|---|---|---|
| MEDIGENE AG | Chief Executive Officer | 31/08/2018 |
| EPIGENOMICS AG | Chief Executive Officer | 30/06/2016 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Thomas Taapken
| Technical University of Berlin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MEDIGENE AG | Health Technology |
| EPIGENOMICS AG | Health Technology |
| SCIBASE HOLDING AB (PUBL) | Health Technology |
| INFLARX N.V. | Health Technology |
| Entreprise privées | 11 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
DVC Deutsche Venture Capital
 DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | Finance |
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Health Technology |
| Scibase AB | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Health Technology |
| Bluehaven Therapeutics AG |
